MarketCap
Facebook
X
TelegramAnnual report 2025
added 02-26-2026
Heron Therapeutics EPS Ratio 2011-2026 | HRTX
EPS is a measure used to assess the financial stability and profitability of a company. EPS (Earnings Per Share) represents the company's net income divided by the number of its outstanding shares. This measure allows investors and analysts to evaluate the return on investment in the company's stock and compare it to other companies in the industry.
The term earnings per share (EPS) represents the portion of a company's earnings, net of taxes and preferred stock dividends, that is allocated to each share of common stock. The figure can be calculated simply by dividing net income earned in a given reporting period (usually quarterly or annually) by the total number of shares outstanding during the same term. Because the number of shares outstanding can fluctuate, a weighted average is typically used.
Calculated as:
EPS = (Net Income - Dividends on Preffered Stock) / Average Outstanding shares[1]
EPS can be calculated as a simple ratio of net income to shares, or in various variations, such as diluted EPS, which takes into account the potential issuance of new shares or convertible securities.
A high EPS ratio usually indicates that the company has good profitability and efficiency in utilizing its assets. However, other factors such as sales growth, debt burden, and the company's competitive position should also be considered.
EPS ratio is an important indicator for investors when making decisions to buy or sell a company's stock. It is also used by analysts to assess the financial condition of the company and its potential for growth and development.
Annual EPS Ratio Heron Therapeutics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -0.12 | -0.09 | -0.8 | -1.67 | -2.24 | -2.5 | -2.5 | -2.44 | -3.65 | -4.56 | -2.95 | -2.87 | -3.42 | -1.91 | -1.96 |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -0.09 | -4.56 | -2.25 |
Quarterly EPS Ratio Heron Therapeutics
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -0.1 | -0.02 | 0.02 | -0.03 | -0.06 | -0.02 | -0.17 | -0.35 | -0.27 | - | -0.38 | -0.55 | -0.63 | - | -0.51 | -0.62 | -0.58 | -0.68 | -0.64 | -0.61 | -0.57 | -0.65 | -0.42 | -0.63 | -0.8 | -0.63 | -0.49 | -0.54 | -0.81 | -1.09 | -0.77 | -0.8 | -1 | -1.22 | -1.24 | -1.17 | -0.92 | -0.87 | -0.63 | -0.74 | -0.7 | -0.71 | -0.66 | -0.78 | -0.74 | -0.75 | -0.84 | -1.01 | -0.85 | -0.51 | -0.45 | -0.46 | -0.85 | -0.02 | -0.02 | -0.05 | -0.04 |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 0.02 | -1.24 | -0.575 |
References
- Khan, T. R., Islam, M. R., Choudhury, T. T., & Adnan, A. M. (2014). How earning per share (EPS) affects on share price and firm value.
EPS Ratio of other stocks in the Biotechnology industry
| Issuer | EPS Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
-15.4 | - | 2.43 % | $ 254 M |  Germany |
 |
Alector
ALEC
|
-1.39 | $ 2.19 | -9.77 % | $ 226 M |  USA |
 |
Acer Therapeutics
ACER
|
-1.66 | - | 2.71 % | $ 14 M | USA |
 |
I-Mab
IMAB
|
-7.66 | - | - | $ 866 M |  China |
 |
Cabaletta Bio
CABA
|
-1.65 | $ 3.34 | 0.45 % | $ 3.9 M | USA |
 |
AgeX Therapeutics
AGE
|
-13.7 | - | -10.17 % | $ 12.2 K | USA |
 |
Biophytis SA
BPTS
|
-0.26 | - | -13.47 % | $ 169 M |  France |
 |
Aeglea BioTherapeutics
AGLE
|
-24.9 | - | - | $ 1.01 B | USA |
 |
Codexis
CDXS
|
-0.89 | $ 1.02 | 1.49 % | $ 74.9 M | USA |
 |
AbCellera Biologics
ABCL
|
-0.49 | $ 3.74 | 3.6 % | $ 1.12 B |  Canada |
 |
Applied Genetic Technologies Corporation
AGTC
|
-0.36 | - | - | $ 26.5 M | USA |
 |
Cerus Corporation
CERS
|
-0.11 | $ 2.6 | 1.37 % | $ 480 M | USA |
 |
Midatech Pharma plc
MTP
|
-31 | - | -18.52 % | $ 27.3 M |  Britain |
 |
Cellectis S.A.
CLLS
|
-2.55 | $ 3.87 | -0.39 % | $ 116 M | France |
 |
ARCA biopharma
ABIO
|
-3.87 | - | 1052.0 % | $ 415 M | USA |
 |
Acorda Therapeutics
ACOR
|
-204 | - | -24.86 % | $ 820 K | USA |
 |
Acasti Pharma
ACST
|
-0.79 | - | 4.01 % | $ 150 M | Canada |
 |
CNS Pharmaceuticals
CNSP
|
-38.9 | $ 3.23 | 2.22 % | $ 1.23 M | USA |
 |
Adverum Biotechnologies
ADVM
|
-6.62 | - | - | $ 86.2 M | USA |
 |
AIkido Pharma
AIKI
|
-2.38 | - | 1.93 % | $ 17.4 M | USA |
 |
Collegium Pharmaceutical
COLL
|
0.54 | $ 41.75 | 0.19 % | $ 1.32 B | USA |
 |
Akero Therapeutics
AKRO
|
-3.75 | - | - | $ 3.67 B | USA |
 |
Akouos
AKUS
|
-2.52 | - | 0.23 % | $ 488 M | USA |
 |
Albireo Pharma
ALBO
|
-1.77 | - | -0.23 % | $ 916 M | USA |
 |
Corcept Therapeutics Incorporated
CORT
|
0.95 | $ 36.14 | 1.23 % | $ 3.75 B | USA |
 |
Allena Pharmaceuticals
ALNA
|
-0.72 | - | 3.16 % | $ 1.9 M | USA |
 |
Amarin Corporation plc
AMRN
|
-0.15 | $ 13.98 | 1.27 % | $ 5.7 B |  Irlanda |
 |
Aileron Therapeutics
ALRN
|
-3.51 | - | 10.36 % | $ 9.8 M | USA |
 |
AlloVir
ALVR
|
-11.7 | - | 4.14 % | $ 49.1 M | USA |
 |
Catalyst Pharmaceuticals
CPRX
|
1.75 | $ 23.77 | 2.99 % | $ 2.91 B | USA |
 |
Alpine Immune Sciences
ALPN
|
-1.73 | - | - | $ 2.17 B | USA |
 |
Corbus Pharmaceuticals Holdings
CRBP
|
-10.3 | $ 8.41 | -1.87 % | $ 36.4 M | USA |
 |
Cardiff Oncology
CRDF
|
-0.69 | $ 1.94 | 0.01 % | $ 130 M | USA |
 |
Curis
CRIS
|
-6.88 | $ 1.1 | -3.51 % | $ 6.94 M | USA |
 |
Aeterna Zentaris
AEZS
|
-0.07 | - | 5.93 % | $ 314 M | Canada |
 |
CorMedix
CRMD
|
-0.91 | $ 7.16 | 0.42 % | $ 364 M | USA |
 |
Ampio Pharmaceuticals
AMPE
|
-10.7 | - | -11.43 % | $ 502 K | USA |
 |
Applied Molecular Transport
AMTI
|
-3.25 | - | - | $ 10.1 M | USA |
|
Champions Oncology
CSBR
|
0.34 | $ 6.14 | 3.89 % | $ 83.9 M | USA |
 |
Aravive
ARAV
|
-2.1 | - | -13.39 % | $ 1.45 M | USA |
 |
Aptose Biosciences
APTO
|
-36.4 | - | -45.71 % | $ 1.2 M | Canada |
 |
Aptinyx
APTX
|
-0.96 | - | -39.0 % | $ 4.57 M | USA |
 |
Citius Pharmaceuticals
CTXR
|
-5.97 | $ 0.72 | -2.34 % | $ 4.84 M | USA |
 |
Athira Pharma
ATHA
|
-2.52 | - | - | $ 269 M | USA |
 |
Aridis Pharmaceuticals
ARDS
|
-1.62 | - | 17.91 % | $ 11.1 M | USA |
 |
Altimmune
ALT
|
-1.34 | $ 4.21 | -2.32 % | $ 299 M | USA |
 |
CEL-SCI Corporation
CVM
|
-0.9 | $ 3.88 | -8.92 % | $ 247 M | USA |